Abstract 3430: Ethnic Differences in the Prevalence and Treatment of Cardiovascular Risk Factors in Outpatients with Peripheral Arterial Disease: Insights from the REACH Registry

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Telly A Meadows ◽  
Deepak L Bhatt ◽  
Alan T Hirsch ◽  
Mark A Creager ◽  
Robert M Califf ◽  
...  

Background : In the United States, African Americans have been reported to have an increased prevalence of peripheral arterial disease (PAD) with poorer outcomes as compared to whites. Whether this can be attributed to differences in the presence and treatment of traditional coronary artery disease (CAD) risk factors versus other factors specifically related to ethnicity is unknown. Methods : We identified 2,235 patients from the United States with documented PAD with and without concomitant CAD and cerebrovascular disease (CVD) at one year enrolled in the REduction of Atherothrombosis for Continued Health (REACH) Registry. We compared the baseline demographics, risk factor profiles, medication use, and one-year outcomes between the 236 African Americans and 1,810 non-Hispanic whites. Results : Among the traditional atherosclerotic risk factors, African Americans were more likely than whites to have diabetes (64.0% vs. 48.6%, p<0.0001), hypertension (95.3% vs. 86.5%, p=0.0001), obesity (45.9% vs. 34.3%, p=0.0002), and isolated PAD (44.9% vs. 28.7%, p<0.0001). In comparison to whites, African Americans were less likely to be on aspirin (62.0% vs. 72.4%, p=0.0009) and lipid-lowering therapy (76.1% vs. 83.2%, p=0.0071), and more likely to have an elevated blood pressure (BP ≥140/90 mmHg: 54.9% vs. 38.1%, p<0.0001) and fasting cholesterol (>200 mg/dL: 41.7% vs. 24.9%, p<0.0001) at baseline. Overall, there were no significant difference in all-cause mortality (4.70% vs. 5.32%, p=0.97) or CV death, MI, or stroke (4.92% vs. 6.20%, p=0.79) between African Americans and whites in this cohort (data adjusted for age and sex). Conclusion : Among U.S. outpatients with PAD, African Americans are more likely than whites to have risk factors for cardiovascular disease, but less likely to receive aspirin or lipid-lowering therapy. In this registry, one-year event rates are relatively high, but similar in both groups.

2005 ◽  
Vol 80 (4) ◽  
pp. 494-498 ◽  
Author(s):  
Daniel G. Federman ◽  
Dana C. Ranani ◽  
Robert S. Kirsner ◽  
Dawn M. Bravata

Vascular ◽  
2021 ◽  
pp. 170853812110439
Author(s):  
Walter Masson ◽  
Martín Lobo ◽  
Leandro Barbagelata ◽  
Graciela Molinero ◽  
Ignacio Bluro

Objective Patients with peripheral artery disease (PAD) are at increased risk of major adverse limb events (MALE). Furthermore, MALE have several clinical implications and a poor prognosis, so prevention is a fundamental issue. The main objective of the present meta-analysis of randomized clinical trials is to evaluate the effect of different lipid-lowering therapies on MALE incidence in patients with PAD. Methods A meta-analysis of randomized studies that evaluated the use of lipid-lowering therapy in patients with PAD and reported MALE was performed, after searching the PubMed/MEDLINE, Embase, ScieLO, Google Scholar, and Cochrane Controlled Trials databases. A fixed- or random-effects model was used. Results Five randomized clinical trials including 11,603 patients were identified and considered eligible for the analyses (5903 subjects were allocated to receive lipid-lowering therapy, while 5700 subjects were allocated to the respective placebo/control arms). The present meta-analysis revealed that lipid-lowering therapy was associated with a lower incidence of MALE (OR: 0.76, 95% confidence interval: 0.66–0.87; I2: 28%) compared to placebo/control groups. The sensitivity analysis shows that the results are robust. Conclusion This study demonstrated that the use of lipid-lowering therapy compared with the placebo/control arms was associated with a marked reduction in the risk of MALE. Physicians involved in the monitoring and treatment of patients with PAD must work hard to ensure adequate lipid-lowering medication in these patients.


2005 ◽  
Vol 10 (2) ◽  
pp. 145-147 ◽  
Author(s):  
Stella S. Daskalopoulou ◽  
Vasilios G. Athyros ◽  
George Hamilton ◽  
Dimitri P. Mikhailidis

Angiology ◽  
2008 ◽  
Vol 60 (4) ◽  
pp. 462-467 ◽  
Author(s):  
Robin Joyce Barrows ◽  
Ulrike Krumsdorf ◽  
Alexandra Zankl ◽  
Hugo Katus ◽  
Christiane Pia Tiefenbacher

Background. Peripheral arterial disease (PAD) indicates generalized atherosclerosis but is still underdiagnosed and undertreated. Methods. Data were collected from patients with PAD from the Department of Cardiology and Angiology, University of Heidelberg, Germany. The prevalence of cardiovascular risk factors and medication were documented. Results. Atherogenic risk factors, cardiovascular disease, and cerebrovascular disease were highly prevalent. By continuous care at the university clinic, in addition to family medicine treatment, the use of platelet inhibitors, antihypertensives, and lipid-lowering therapy was increased. Ankle—brachial index and walking distance improved. Conclusion. Long-term treatment at the university clinic had positive effects on atherogenic risk factors. The regular use of secondary preventive medication was improved. Still, this patient population remained undertreated and showed a high incidence of vascular event rates and a need for vascular interventions. This study implies the importance of both specialists and general practitioners in the care of these individuals.


2007 ◽  
Vol 45 (5) ◽  
pp. 936-943 ◽  
Author(s):  
Harm H.H. Feringa ◽  
Stefanos E. Karagiannis ◽  
Virginie H. van Waning ◽  
Eric Boersma ◽  
Olaf Schouten ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document